334 related articles for article (PubMed ID: 31824475)
1. Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans.
Russlies J; Fähnrich A; Witte M; Yin J; Benoit S; Gläser R; Günter C; Eming R; Erdmann J; Gola D; Gupta Y; Holtsche MM; Kern JS; König IR; Kiritsi D; Lieb W; Sadik CD; Sárdy M; Schauer F; van Beek N; Weidinger A; Worm M; Zillikens D; Schmidt E; Busch H; Ibrahim SM; Hirose M
Front Immunol; 2019; 10():2200. PubMed ID: 31824475
[TBL] [Abstract][Full Text] [Related]
2. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?
Amber KT; Zikry J; Hertl M
HLA; 2017 Mar; 89(3):127-134. PubMed ID: 28101965
[TBL] [Abstract][Full Text] [Related]
3. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
4. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
Julio TA; Vernal S; Massaro JD; Silva MC; Donadi EA; Moriguti JC; Roselino AM
Immunol Res; 2018 Oct; 66(5):567-576. PubMed ID: 30220011
[TBL] [Abstract][Full Text] [Related]
5. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
6. miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid.
Qiu L; Zhang L; Qi R; Gao X; Chen H; Xiao T
Dis Markers; 2020; 2020():9505312. PubMed ID: 32399091
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
[TBL] [Abstract][Full Text] [Related]
8. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
[TBL] [Abstract][Full Text] [Related]
9. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
[TBL] [Abstract][Full Text] [Related]
12. Bullous Pemphigoid and Neurologic Diseases: Toward a Specific Serologic Profile?
Petrera MR; Tampoia M; Guida S; Abbracciavento L; Fumarulo R; Foti C
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):662-664. PubMed ID: 30062977
[TBL] [Abstract][Full Text] [Related]
13. Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans.
Schwarm C; Gola D; Holtsche MM; Dieterich A; Bhandari A; Freitag M; Nürnberg P; Toliat M; Lieb W; Wittig M; Franke A; Worm M; Sticherling M; Ehrchen J; Günther C; Gläser R; Peitsch WK; Sárdy M; Eming R; Hertl M; Benoit S; Goebeler M; Pföhler C; Kunz M; Kreuter A; van Beek N; Erdmann J; Busch H; Zillikens D; Sadik CD; Hirose M; König IR; Schmidt E; Ibrahim SM;
Orphanet J Rare Dis; 2021 May; 16(1):228. PubMed ID: 34011352
[TBL] [Abstract][Full Text] [Related]
14. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid.
Mersmann M; Dworschak J; Ebermann K; Komorowski L; Schlumberger W; Stöcker W; Zillikens D; Probst C; Schmidt E
Arch Dermatol Res; 2016 Jan; 308(1):31-8. PubMed ID: 26498290
[TBL] [Abstract][Full Text] [Related]
15. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
[TBL] [Abstract][Full Text] [Related]
16. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
18. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
19. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
